Cytokinetics, Inc. (CYTK) Insider Caryn Gordon Mcdowell Sells 2,709 Shares
Cytokinetics, Inc. (NASDAQ:CYTK) insider Caryn Gordon Mcdowell sold 2,709 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $9.00, for a total value of $24,381.00. Following the transaction, the insider now directly owns 15,077 shares in the company, valued at approximately $135,693. The transaction was disclosed in a filing with the SEC, which is available at this link.
Caryn Gordon Mcdowell also recently made the following trade(s):
- On Thursday, November 2nd, Caryn Gordon Mcdowell sold 4,260 shares of Cytokinetics stock. The stock was sold at an average price of $12.94, for a total value of $55,124.40.
Shares of Cytokinetics, Inc. (CYTK) traded down $0.05 during midday trading on Thursday, reaching $8.80. The company’s stock had a trading volume of 210,435 shares, compared to its average volume of 502,285. The company has a current ratio of 7.60, a quick ratio of 7.60 and a debt-to-equity ratio of 0.14. Cytokinetics, Inc. has a 12 month low of $7.00 and a 12 month high of $17.20. The stock has a market cap of $474.19, a P/E ratio of -5.30 and a beta of 1.61.
Hedge funds and other institutional investors have recently modified their holdings of the business. Birchview Capital LP purchased a new stake in Cytokinetics during the 3rd quarter worth about $145,000. Piedmont Investment Advisors LLC purchased a new stake in Cytokinetics during the 3rd quarter worth about $159,000. GSA Capital Partners LLP purchased a new stake in Cytokinetics during the 3rd quarter worth about $187,000. BNP Paribas Arbitrage SA increased its holdings in Cytokinetics by 4,464.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 13,036 shares during the period. Finally, SG Americas Securities LLC increased its holdings in Cytokinetics by 73.3% during the 2nd quarter. SG Americas Securities LLC now owns 14,306 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 6,052 shares during the period. Institutional investors own 73.61% of the company’s stock.
Several equities analysts recently issued reports on the company. Cantor Fitzgerald reissued a “hold” rating and set a $10.00 target price on shares of Cytokinetics in a research note on Wednesday. Needham & Company LLC lowered Cytokinetics from a “strong-buy” rating to a “buy” rating and decreased their target price for the stock from $22.00 to $12.00 in a research note on Wednesday, November 29th. Morgan Stanley reissued an “overweight” rating and set a $17.00 target price (down previously from $25.00) on shares of Cytokinetics in a research note on Wednesday, November 22nd. ValuEngine lowered Cytokinetics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 21st. Finally, JMP Securities reissued an “outperform” rating and set a $13.00 target price (down previously from $17.00) on shares of Cytokinetics in a research note on Tuesday, November 21st. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $17.64.
TRADEMARK VIOLATION WARNING: “Cytokinetics, Inc. (CYTK) Insider Caryn Gordon Mcdowell Sells 2,709 Shares” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/18/cytokinetics-inc-cytk-insider-caryn-gordon-mcdowell-sells-2709-shares.html.
Cytokinetics Company Profile
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.